---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-042800"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T01:06:40.104150+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Candel presents second enLIGHTEN candidate at AACR; induces TLS, enhances anti-PD-1 in mice

## Summary
- Second multimodal immunotherapy candidate from enLIGHTEN platform targets tertiary lymphoid structures (TLS) in solid tumors.
- Two payload combinations, predicted via enLIGHTEN analytics, induced TLS, monotherapy anti-tumor activity, and boosted anti-PD-1 response in mouse models.
- Milestone accelerated from Q3 2024 to April 2024, validating platform speed.
- TLS induction is a novel strategy to improve anti-tumor immunity; data presented at AACR April 5-10, 2024.

## SEC filing metadata
- accession: 0000950170-24-042800
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017024042800/0000950170-24-042800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017024042800/cadl-20240409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-042800
- JSON: https://secwatch.observer/filing/0000950170-24-042800.json
- Plain text: https://secwatch.observer/filing/0000950170-24-042800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.